share_log

Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate

Benzinga ·  May 2 16:00

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.77) by 14.69 percent. The company reported quarterly sales of $108.833 million which missed the analyst consensus estimate of $116.009 million by 6.19 percent. This is a 8.30 percent increase over sales of $100.496 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment